Amgen's new cancer drug treatment to cost US$178,000
Add BT as a preferred sourceSan Francisco
AMGEN Inc's leukaemia drug Blincyto will cost US$178,000 for a standard course of treatment, continuing a trend of high prices for immunotherapy, the newest wave of cancer treatments.
The price includes two US$89,000 cycles of therapy, the median duration of treatment for patients who responded in clinical studies, said Danielle Bertrand, a spokeswoman for Amgen, the second-biggest US biotechnology company. Each cycle consists of four weeks of treatment.
TRENDING NOW
Profit with purpose: Kim Choo Kueh Chang’s pivot from public listing to protecting heritage
Singapore Kitchen CEO, senior manager charged with alleged fraud, falsifying accounts; both to stay in jobs for now
Yeo’s, Tiger Beer and now Gardenia – flight of food manufacturing from Singapore might be just as planned
Should you sacrifice some CPF Life income in favour of ILPs? Tread carefully
